Top 5 benign urology headlines you missed in September 2025

The month of September offered plenty of new research and expert insight in benign urological conditions. This included results from the RAPID I study evaluating the FloStent device for benign prostatic hyperplasia (BPH), a report on innovative stone-treating technology, an update to the American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline on recurrent uncomplicated urinary tract infections (uUTIs) in women, and more.

Here, we collect 5 key articles and videos in the field of benign urology from September 2025. Click the headlines to access the full article/video.

1. FloStent device shows efficacy for acute urinary retention due to BPH

Results from the RAPID I study showed that the FloStent device enabled immediate catheter-free voiding in men with BPH-related urinary retention, with 73% of patients remaining catheter-free at 3 months. The first-in-human study enrolled 11 men awaiting transurethral resection of the prostate, all of whom achieved catheter independence following implantation. Symptom scores, flow rates, and quality of life measures improved, and adverse events were mild and no serious complications occurred. Investigators noted FloStent may serve as an effective interim therapy and a potential first-line interventional treatment, offering rapid relief and preserving function.¹

2. Optimizing BPH care: Experts discuss HoLEP, MISTs, and shared decision-making

In a recent interview with Urology Times®, Kanika Searvance, MD, and Yasin Bhanji, MD, of Georgia Urology discussed the key role for holmium laser enucleation of the prostate (HoLEP) in the BPH landscape given its effectiveness in larger prostates. They specifically outlined the advantages of HoLEP compared with other options, emphasizing its size-independence, low retreatment rate, and quick recovery. For these reasons and despite the learning curve, Searvance and Bhanji noted the growing popularity and future prominence of HoLEP in the current BPH treatment landscape.

3. SURE procedure linked with lower health care utilization vs URS

Two-year data from the ASPIRE trial, presented at the 2025 World Congress of Endourology and Uro-Technology, showed that steerable ureteroscopic renal evacuation (SURE) with the CVAC Aspiration System significantly reduced health care consumption events compared with ureteroscopy (URS). Among 101 patients with 7 mm- to 20-mm renal stones, only 4.3% of those treated with SURE experienced an HCE at 2 years vs 20% in the URS arm (P = .02), reflecting a 73% risk reduction. Patients undergoing SURE also had a longer average event-free period (701.6 vs 608.2 days). Safety outcomes were comparable.²

4. A. Lenore Ackerman, MD, on balancing test results with clinical judgement for UTI

The American Urological Association, in collaboration with the Canadian Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, recently released an amendment to the guideline on recurrent uUTIs in women.³ The amendment specifically notes a greater value of a negative urinalysis in ruling out UTI.

In a recent interview with Urology Times, guideline amendment chair A. Lenore Ackerman, MD, PhD, discusses how clinicians should balance diagnostic test results with their own clinical judgment in ambiguous cases. Ackerman is a urogynecologist at the University of California, Los Angeles.

5. Kevin Koo, MD, MPH, on a digital stone measurement tool for ureteroscopy

A recent study published in Urology suggests that the ability to take stone measurements intraoperatively may have significant implications for surgical decision-making and procedural efficiency.⁴

Senior author Kevin Koo, MD, MPH, recently sat down with Urology Times® to outline the background and key findings from the study. Koo is a urologist at Mayo Clinic in Rochester, Minnesota.

Overall, Koo noted, “The findings support our hypothesis that empowering kidney stone surgeons with information about the size of the stones that they're treating and the size of the fragments that are produced gives them actionable information about how they can optimize what they're doing in surgery and then optimize patient outcomes after surgery.”

REFERENCES

1. Chughtai B, Polo J, Perscky I, Urena R, Kadlec A, Elterman D. First use of the FloStent for catheter-dependent urinary retention secondary to BPH: additional results from the RAPID I study. Urology. Published online September 16, 2025. doi:10.1016/j.urology.2025.09.018

2. Calyxo debuts reverse deflection CVAC System and reveals groundbreaking two-year ASPIRE data at WCET 2025, underscoring the technology’s role in advancing endourology. News release. Calyxo. September 11, 2025. Accessed September 11, 2025. https://www.businesswire.com/news/home/20250911893155/en/Calyxo-Debuts-Reverse-Deflection-CVAC-System-and-Reveals-Groundbreaking-Two-Year-ASPIRE-Data-at-WCET-2025-Underscoring-the-Technologys-Role-in-Advancing-Endourology

3. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). American Urological Association. Accessed September 4, 2025. https://www.auanet.org/guidelines-and-quality/guidelines/recurrent-uti

4. Krueger ABC, Smith DM, Parzych AT, et al. Impact of intraoperative digital stone measurement on surgeon decision making in ureteroscopy. Urology. 2025:S0090-4295(25)00643-0. doi:10.1016/j.urology.2025.06.064